Literature DB >> 1168024

Photocoagulation in venous occlusive disease.

K A Gitter, G Cohen, B W Baber.   

Abstract

Fifty-one eyes with branch or tributary retinal venous occlusive disease underwent photocoagulation (1970-1973) after certain criteria were met: reduced visual acutity, fluorescein angiographic documentation of vessel permeability changes, and either dye leakage into the macula or neovascularization of the retina, or both. Eighty-four percent of the eyes responded to treatment with an improvement or stabilization in visual acuity, a reduction in collateral vessel caliber and permeability, and reduced dye accumlation in the macular area and increased fluorescein transit time. Photocoagulation is an affective means of reducing macular edema resulting from vascular compensatory changes following venous occlusion and decreases the risk of vitreous hemorrhage from sites of retinal neovascularization.

Entities:  

Mesh:

Year:  1975        PMID: 1168024     DOI: 10.1016/0002-9394(75)90795-3

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  5 in total

1.  Photocoagulation in retinal branch vein occlusion.

Authors:  F A Gutman; H Zegarra; A Rauer; N Zakov
Journal:  Trans Am Ophthalmol Soc       Date:  1980

Review 2.  Photocoagulation in retinal vein occlusion.

Authors:  S C Sedney
Journal:  Doc Ophthalmol       Date:  1976-01-28       Impact factor: 2.379

3.  A prospective study of xenon arc photocoagulation for central retinal vein occlusion.

Authors:  D R May; M L Klein; G A Peyman
Journal:  Br J Ophthalmol       Date:  1976-12       Impact factor: 4.638

4.  Treatment of neovascularization secondary to branch retinal vein obstruction.

Authors:  D B Archer; N Michalopoulos
Journal:  Int Ophthalmol       Date:  1981-05       Impact factor: 2.031

5.  Xenon arc panretinal photocoagulation for central retinal vein occlusion: a randomised prospective study.

Authors:  D R May; M L Klein; G A Peyman; M Raichand
Journal:  Br J Ophthalmol       Date:  1979-11       Impact factor: 4.638

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.